Il rapporto
Analisi approfondite sul finanziamento aziendale, strategie di crescita e approfondimenti di mercato dalle aziende più innovative del mondo
230 report e oltre
Candid Therapeutics raises $370M Series A at $1.2B valuation
Candid Therapeutics raises $370M in Series A at $1.2B valuation. Developing novel therapeutics for autoimmune diseases...
Candid Therapeutics Raises $370M in Series A
Candid Therapeutics, a Biotech company based in San Francisco, CA, has raised $370M in Series A at a $1.2B valuation led by Venrock, Fairmount, TCGX.
Kailera Therapeutics Raises $400 Million in Series A - October 2024
Kailera Therapeutics announced $400 Million in Series A funding at a Undisclosed valuation. Kailera Therapeutics raised a massive $400 million Series A to develop clinical-stage injectable and oral therapies for chronic weight management and ...
Electra Therapeutics Raises $183 Million in Series C - October 22, 2024
Electra Therapeutics announced $183 Million in Series C funding at a Undisclosed valuation. Electra Therapeutics raised an oversubscribed $183 million Series C to advance clinical trials for novel immunology therapies targeting autoimmune and...
Candid Raises $200M in Series D
Candid, a AI/ML company based in San Francisco, CA, has raised $200M in Series D at a $1.5B valuation led by General Catalyst, Index Ventures.
Candid raises $200M Series D at $1.5B valuation
Candid raises $200M in Series D at $1.5B valuation. AI for business intelligence...
Arnatar Therapeutics raises $52M Series A
Arnatar Therapeutics raises $52M in Series A. Developing therapeutics for autoimmune and inflammatory diseases...
Denali Therapeutics raises $217M Series C at $5B valuation
Denali Therapeutics raises $217M in Series C at $5B valuation. Neurodegeneration therapeutics...
Strand Therapeutics raises $153M Series B
Strand Therapeutics raises $153M in Series B. mRNA-based therapeutics developer with novel cancer treatment platform...
Visualizzazione di 9 report • Pagina 1 • Categoria: all
Rimani avanti rispetto al mercato
Ricevi insight settimanali nella tua casella di posta. Niente spam, solo intelligenza.